Zobrazeno 1 - 10
of 257
pro vyhledávání: '"Mark J. O’Connor"'
Autor:
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D. Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J. Arenas, Helena Verdaguer, Fernando J. Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V. Forment, Mark J. O’Connor, Mark Albertella, Judith Balmaña, Violeta Serra
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is
Externí odkaz:
https://doaj.org/article/68b3f150f248467b98d10c77d2ec9d7a
Autor:
Zhi Ling Teo, Mark J. O’Connor, Stephanie Versaci, Kylie A. Clarke, Emmaline R. Brown, Luke W. Percy, Keilly Kuykhoven, Christopher P. Mintoff, Peter Savas, Balaji Virassamy, Stephen J. Luen, Ann Byrne, Sneha Sant, Geoffrey J. Lindeman, Phillip K. Darcy, Sherene Loi
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour g
Externí odkaz:
https://doaj.org/article/bce6df774b064a2787512a67c74201f2
Autor:
Tian Ge, Marguerite R. Irvin, Amit Patki, Vinodh Srinivasasainagendra, Yen-Feng Lin, Hemant K. Tiwari, Nicole D. Armstrong, Barbara Benoit, Chia-Yen Chen, Karmel W. Choi, James J. Cimino, Brittney H. Davis, Ozan Dikilitas, Bethany Etheridge, Yen-Chen Anne Feng, Vivian Gainer, Hailiang Huang, Gail P. Jarvik, Christopher Kachulis, Eimear E. Kenny, Atlas Khan, Krzysztof Kiryluk, Leah Kottyan, Iftikhar J. Kullo, Christoph Lange, Niall Lennon, Aaron Leong, Edyta Malolepsza, Ayme D. Miles, Shawn Murphy, Bahram Namjou, Renuka Narayan, Mark J. O’Connor, Jennifer A. Pacheco, Emma Perez, Laura J. Rasmussen-Torvik, Elisabeth A. Rosenthal, Daniel Schaid, Maria Stamou, Miriam S. Udler, Wei-Qi Wei, Scott T. Weiss, Maggie C. Y. Ng, Jordan W. Smoller, Matthew S. Lebo, James B. Meigs, Nita A. Limdi, Elizabeth W. Karlson
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-16 (2022)
Abstract Background Type 2 diabetes (T2D) is a worldwide scourge caused by both genetic and environmental risk factors that disproportionately afflicts communities of color. Leveraging existing large-scale genome-wide association studies (GWAS), poly
Externí odkaz:
https://doaj.org/article/e049f828882147afa27dd2a692f0bc18
Autor:
Anabel Zelceski, Paola Francica, Lea Lingg, Merve Mutlu, Colin Stok, Martin Liptay, John Alexander, Joseph S. Baxter, Rachel Brough, Aditi Gulati, Syed Haider, Maya Raghunandan, Feifei Song, Sandhya Sridhar, Josep V. Forment, Mark J. O’Connor, Barry R. Davies, Marcel A.T.M. van Vugt, Dragomir B. Krastev, Stephen J. Pettitt, Andrew N.J. Tutt, Sven Rottenberg, Christopher J. Lord
Publikováno v:
Cell Reports, Vol 42, Iss 5, Pp 112484- (2023)
Summary: The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity to poly (ADP-Ribose
Externí odkaz:
https://doaj.org/article/9820d80912b4460eb12878b12cea41b1
Autor:
Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O’Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied th
Externí odkaz:
https://doaj.org/article/42e14e70567c4dc0ac16e7566635a844
Autor:
Jacqueline H. L. Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W. G. Wijnhoven, Valeria Follia, Neil James, Paul M. Farrington, Ankur Karmokar, Sophie E. Willis, Jonathan Cairns, Jenni Nikkilä, David Beattie, Gillian M. Lamont, M. Raymond V. Finlay, Joanne Wilson, Aaron Smith, Lenka Oplustil O’Connor, Stephanie Ling, Stephen E. Fawell, Mark J. O’Connor, Simon J. Hollingsworth, Emma Dean, Frederick W. Goldberg, Barry R. Davies, Elaine B. Cadogan
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
DNA-dependent protein kinase (DNA-PK) plays a major role in the DNA damage response upon double-strand break formation. Here, the authors show that the DNA-PK inhibitor AZD7648, enhances the activity of radiotherapy, chemotherapy and the PARP inhibit
Externí odkaz:
https://doaj.org/article/7547983126794fc0a17cf1c4d462a298
Autor:
Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres‐Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra
Publikováno v:
EMBO Molecular Medicine, Vol 10, Iss 12, Pp 1-16 (2018)
Abstract Poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2‐related cancers. A test to identify additional HRR‐deficient tumors will help to
Externí odkaz:
https://doaj.org/article/338354bc305a441ba1ed0aea5e8d5f0d
Autor:
Tatiana Moiseeva, Brian Hood, Sandy Schamus, Mark J. O’Connor, Thomas P. Conrads, Christopher J. Bakkenist
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
ATR kinase activity is essential for slowing replication forks and preventing DNA replication in cells with DNA damage. Here the authors show that ATR inhibition leads to Cdc7 phosphorylation of GINS, leading to origin firing.
Externí odkaz:
https://doaj.org/article/e06d11873a0341e4bb21a45631b70175
Autor:
Josep V. Forment, Elisabetta Leo, Mark J. O'Connor, Miika Ahdesmäki, Daniel Barrell, Sabrina Bentouati, James Hall, Giuditta Illuzzi, Joshua Armenia, Alessandro Galbiati, Kunzah Jamal
Supplementary Figure S1. A, Workflow to generate isogenic HRR KO cell models (see also Methods). B, Dose-response curve for SKOV3 BRCA2 KO isogenic pairs treated with olaparib for 10-14 days in clonogenic survival assays. Results are shown as mean of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6fcc1c478ec183e92c279c578f5df19
https://doi.org/10.1158/2767-9764.22544930
https://doi.org/10.1158/2767-9764.22544930
Autor:
Josep V. Forment, Elisabetta Leo, Mark J. O'Connor, Miika Ahdesmäki, Daniel Barrell, Sabrina Bentouati, James Hall, Giuditta Illuzzi, Joshua Armenia, Alessandro Galbiati, Kunzah Jamal
PARP inhibitors (PARPi) are currently indicated for the treatment of ovarian, breast, pancreatic, and prostate cancers harboring mutations in the tumor suppressor genes BRCA1 or BRCA2. In the case of ovarian and prostate cancers, their classification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12398cd93bb5dc572032d161238911b7
https://doi.org/10.1158/2767-9764.c.6550787.v1
https://doi.org/10.1158/2767-9764.c.6550787.v1